Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma into the Priority Review Program

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Inclusion of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma into the Priority Review Program

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis